Study finds Pfizer’s antiviral has little to no benefit for young adults, and WHO says BA.5 omicron subvariant accounted for 74% of cases in past week
Pfizer’s COVID antiviral, Paxlovid, appears to have little to no benefit for young adults, although it still reduces the risk of hospitalization or death in older adults, according to a new Israeli study. Data from the study of 109,000 patients could renew questions about the US government’s use of Paxlovid, which has become the gold … Read more